Valuation: Novacyt

Market Cap 33.33M 38.15M 30.84M 28.31M 53.55M 3.67B 54.51M 368M 144M 1.8B 143M 140M 6.19B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 35.29M 40.39M 32.65M 29.97M 56.69M 3.89B 57.71M 389M 153M 1.9B 152M 148M 6.56B EV / Sales 2026 *
1.16x
EV / Sales 2027 * 1.1x
Free-Float
99.83%
Yield 2026 *
-
Yield 2027 * -
1 day-5.90%
Current year-5.90%
Current year 0.48
Extreme 0.48
0.48
1 year 0.48
Extreme 0.48
0.51
3 years 0.48
Extreme 0.48
1.25
5 years 0.48
Extreme 0.48
5.77
10 years 0
Extreme 0
16
Manager TitleAgeSince
Chief Executive Officer 53 2024-04-30
Director of Finance/CFO 44 2019-12-31
Chief Operating Officer - 2021-10-31
Director TitleAgeSince
Director/Board Member 75 2006-07-02
Director/Board Member 60 2017-06-26
Director/Board Member 44 2024-01-01
Change 5-day change 1-year change 3-year change Capi.($)
-5.90%-.--% - - 34.85M
+3.75%+3.99%-30.02%-33.98% 636M
-9.12%+33.56%+188.66% - 565M
-4.31%-3.87%-41.84%+24.39% 119M
+4.87%-1.75%+9.80%+75.00% 104M
Average -2.14%+4.55%+31.65%+21.81% 356.02M
Weighted average by Cap. -2.04%+11.67%+58.71%-12.70%

Financials

2026 *2027 *
Net sales 30.52M 34.94M 28.24M 25.92M 49.04M 3.37B 49.92M 337M 132M 1.65B 131M 128M 5.67B 34.86M 39.9M 32.26M 29.6M 56M 3.84B 57.01M 385M 151M 1.88B 150M 146M 6.48B
Net income - -
Net Debt 1.96M 2.24M 1.81M 1.66M 3.14M 216M 3.2M 21.58M 8.46M 106M 8.4M 8.22M 363M 4.84M 5.54M 4.48M 4.11M 7.78M 534M 7.92M 53.42M 20.94M 261M 20.8M 20.34M 900M
Logo Novacyt
Novacyt develops, produces, and sells in vitro and molecular diagnostic products products and instruments, primarily for the genomic medicine sector. Net sales break down by activity as follows: - development of genomic solutions and services (79.7%; Yourgene Health): sale of molecular diagnostic and screening solutions across reproductive health and precision medicine; - manufacturing and sale of reagents and kits for the screening of infectious diseases (20.3%; Primer Design). The group also offers qPCR tests and high-performance workflows for use in the fields of human health, agriculture, veterinary medicine and the environment, aimed at healthcare organisations and the research industry, as well as sequencing services (genome/exome) for the pharmaceutical research sector. Net sales are distributed geographically as follows: France (10.3%), the United Kingdom (20.9%), Europe (20%), Asia/Pacific (28.7%), the Americas (14.5%), Middle East (3.2%) and Africa (2.4%).
Employees
216

Annual profits - Rate of surprise